Stock·NYSE·Healthcare
Molina Healthcare Inc. (MOH)
- Market cap
- $10.82B
- P/E
- 2,304.00
- Dividend yield
- 0.00%
- Street target
- $209.00median of 19 analysts
- 52-week range
- $121.06 $244.89
The short version
Where MOH stands today, in four lines, and what CleaRank Financial AI makes of it.
MOH at a glance
Molina Healthcare Inc. (MOH): Hold, 58/100 on CleaRank's AI score.
- Trend Up: the price is above both its 50- and 200-day moving averages ($199.43 and $183.58).
- Insiders Insiders sold $32.7M and bought $1.7M over the last 18 months.
Figures as of October 17, 2026.
CleaRank Financial AI
CleaRank rates Molina Healthcare Inc. (MOH) Hold, with a model score of 58/100.
Trend is the factor that lifts the score most. The price is 12.95% above its 200-day average and 3.98% above its 50-day average, while the 50-day average is 8.63% above the 200-day. Revenue growth is the largest drag: revenue fell 5.70%, 13.8 percentage points slower than the sector median. The 50-day average is $199.43 and the 200-day is $183.58. Across the past year, the price climbed 9.97%.
Only on CleaRank
Figures we compute ourselves from MOH's own price, earnings and insider-filing history. Tap one to see it in context.
Price and trading
The chart, today's range and how far the price has moved over each period.
Trend checks
4/4Price above its 50-day average ›
The price of $207.36 is 4.0% above the 50-day simple moving average of $199.43.Price above its 200-day average ›
The price is 13.0% above the 200-day simple moving average of $183.58.50-day average above the 200-day ›
The 50-day average ($199.43) is 8.6% above the 200-day average ($183.58), the arrangement of a rising longer-term trend.In the upper half of its 52-week range ›
The price sits at 70% of its 52-week range, between $121.06 and $244.89.
MOH share price
Pick a period: each tab shows how far MOH has moved over it, to the last close.
Today's trading
Where MOH sits inside today's range and its 52-week range.
Fundamentals
Valuation against the sector, and the revenue and earnings behind it.
Valuation and quality checks
1/2P/S below the sector median ›
The price-to-sales ratio of 0.26 is 92.3% below the sector median of 3.4.Profitable over the last 12 months ›
Net income over the last 12 months was $-7.0M on revenue of $42.5B, a net margin of -0.0%.
Key statistics
The headline figures for MOH.
As of October 17, 2026, MOH trades at $207.36, with a market value of $10.82B and a P/E ratio of 2,304.00.
What the numbers say
CleaRank Financial AI's reading of MOH's valuation, growth and risks.
MOH is valued at 0.26 times sales, a multiple that is 92.4% below the sector median of 3.4. The company's market capitalisation of $10.8B puts its size in context.
MOH is currently unprofitable: its net margin is -0.02%, its operating margin is 1.40%, and its return on equity of -0.16% trails the sector median of 7.3%. Revenue fell 5.70%, which leaves the company 13.8 percentage points slower than the sector median of 8.1%. Finally, debt-to-equity stands at 0.95, adding weight to the balance sheet picture.
Analysts forecast EPS of $5.25 for this fiscal year, a fall of 52.4%. For the year after, they expect $8.55, which would be growth of 167.5%.
Expect day-to-day swings: on an average session MOH has moved 2.38%. The stock trades 15.33% below its 52-week high of $244.89. Over the last 18 months insiders sold $32.7M worth of shares and bought $1.7M. Insider sales of this type are frequently scheduled ahead of time, so they tell less than open-market buying does.
MOH against the Healthcare sector
How MOH compares with the median Healthcare stock CleaRank tracks.
Price to sales vs sector: On price-to-sales, the yardstick used here in place of P/E, MOH trades at 0.2612x, far below the sector average of 3.40x.
Return vs XLV: Since May 6, 2025, MOH has lost 34.4% against a gain of 31.6% for XLV.
Performance against XLV
MOH and the Healthcare sector fund over the same days.
Revenue and earnings
How much MOH sells, and how much of it becomes profit.
Revenue growth: Revenue grew 11.7% in FY2025 to $45.4B, from $40.7B a year earlier.
Profit margin: The net margin was 1.0% in FY2025, down from 2.9% the year before.
Profitable: MOH earned $472M in FY2025.
AI analysis and technicals
CleaRank's score and reasoning, the indicators behind it, and what the price moves with.
Momentum checks
3/3RSI not overbought or oversold ›
The 14-day RSI is 58.4, in neutral territory.RSI above 50 ›
An RSI of 58.4 is above the 50 midpoint, so buyers have had the upper hand over the last 14 days.MACD line above zero ›
The MACD line is positive, so the 12-day average is above the 26-day average.
CleaRank AI analysis of MOH
The score, the reasoning behind it, and what could move the price next.
MOH is in an uptrend. The price of $207.36 sits 12.95% above its 200-day average of $183.58 and 3.98% above its 50-day average of $199.43. The 50-day average is 8.63% above the 200-day, a configuration that backs up the trend instead of working against it. On its 52-week range of $121.06 to $244.89, the price stands at 70%, which leaves it 15.33% below the high.
Short-term and long-term readings disagree. Over the past month the price climbed 2.54%, yet over the past three months it slid 7.99%, and across the past year it gained 9.97%. Meanwhile the 14-day RSI sits at 58.4, which is neutral territory, and the MACD line is positive.
Rating reaffirmed ›
Wells Fargo kept its Equal-Weight rating on July 28, 2026.
Source: Analyst action, Wells Fargo, July 28, 2026
No risks flagged.
- The two levels closest to the price are the 52-week high at $244.89 above it and the 20-day EMA at $200.23 below it.
- The 14-day RSI is 58.4, which is neutral, and the MACD line is positive. Readings above 70 or below 30 point to stretched momentum.
The uptrend depends on MOH holding above its 50-day average at $199.43 and its 200-day average at $183.58. A close below the 50-day would be the first sign of weakness. If the price pulls back, the first level it would reach is the 20-day EMA at $200.23.
The 52-week high at $244.89 is the next level overhead.
Technical indicators
Momentum and trend for MOH, from its daily closes.
As of October 17, 2026, with MOH at $207.36, its 14-day RSI is 58.4 (neutral territory), its 50-day simple moving average is $199.43 and its 200-day is $183.58.
Calculated by CleaRank on daily closes as of October 17, 2026: Wilder's 14-day RSI, 50- and 200-day simple moving averages, MACD line (12, 26).
What MOH moves with
Correlation of daily returns over one year: +1 moves in step, 0 has no link, -1 moves the opposite way.
As of October 17, 2026, MOH's 1-year correlation of daily returns is +0.02 with S&P 500 (SPY), -0.02 with Nasdaq 100 (QQQ), -0.14 with Bitcoin (BTC) and -0.05 with gold (XAU).
What Wall Street expects
The analysts' target range and how their ratings split.
Analysts checks
2/3Most analysts rate it a buy ›
4 of 19 analysts rate it a buy or strong buy, 14 a hold and 1 a sell.Median target above the price ›
The median 12-month target of $209.00 is 0.8% above the price.More buy ratings than three months ago ›
4 of 19 rate it a buy now, against 3 of 19 three months ago.
MOH Wall Street View
12-month price targets
Ratings
Recent rating actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Jul 28, 2026 | Wells Fargo | Maintains | Equal-Weight |
| Jul 24, 2026 | Truist Securities | Maintains | Hold |
| Jul 24, 2026 | RBC Capital | Maintains | Sector Perform |
| Jul 24, 2026 | Barclays | Maintains | Underweight |
| Jul 14, 2026 | TD Cowen | Maintains | Hold |
| Jul 14, 2026 | Truist Securities | Maintains | Hold |
As of October 17, 2026, 19 Wall Street analysts cover MOH: 4 rate it a buy or strong buy, 14 a hold and 1 a sell or strong sell. Their 12-month price targets range from $147.00 to $266.00, with a median of $209.00, 0.8% above the price of $207.36.
Source: TwelveData analyst consensus. Targets and ratings belong to the analysts, not to CleaRank.
A trade plan, if you want one
Entry, stop and target levels from the moving averages and recent volatility. Educational, not advice.
MOH trade plan
Entry, stop and target levels, sized to your account. Change the bias or the risk and every level updates.
Entry Strategies pick an entry style
Risk management
Profit targets (Based on Conservative Entry)
These levels come from MOH's moving averages and recent volatility, not from a forecast. Educational levels, not financial advice; the full disclaimer is at the foot of the page.
Risk profile
How much MOH tends to move, against the market and on its own.
The long record
MOH's worst falls and recoveries, what $10,000 became, and which months have been kind to it.
Track record checks
1/4Average daily move under 2% ›
The price has moved 2.38% on an average day (30-day standard deviation of daily returns).Recovered from its worst fall ›
The worst fall was 70.3%, from March 2024 to February 2026; the price is still 49.7% below that peak.Most 1-year holds ended higher ›
69% of 1-year holding periods in the last 10 years ended with a gain.Beat the S&P 500 since the chart begins ›
$10,000 invested in October 2016 is now worth $37,068, against $42,055 in the S&P 500 (SPY).
MOH Drawdowns & Recovery
As of October 17, 2026, MOH's worst peak-to-trough fall over the last 10 years with dividends reinvested was -70.3% (March 2024 to February 2026); it is still 49.7% below that peak, and 69% of 1-year holding periods ended with a gain.
From weekly closing values with dividends reinvested. A drawdown is the fall from the highest value reached so far to a later low.
Growth of $10,000
What $10,000 put into MOH in October 2016 is worth now, against the same amount in the S&P 500.
Against the market: MOH trailed the S&P 500 over this period: $37,068 against $42,055.
A $10,000 investment in MOH in October 2016 would be worth about $37,068 today with dividends reinvested, compared with about $42,055 for the same investment in the S&P 500 benchmark (also with dividends reinvested).
Seasonal patterns
Which calendar months have been kind to MOH, and which have not.
Strongest month, April: an average of +7.12%, up in 7 of 10 years.
Weakest month, February: an average of -4.18%, up in 4 of 10 years.
This month, October: has averaged -0.95%, up in 4 of 9 years. Past seasonality does not repeat on schedule.
Over the last 10 years, MOH's strongest calendar month has been April (average +7.12%, up in 7 of 10 years) and its weakest February (average -4.18%, up in 4 of 10 years).
Average return for each calendar month over the last 10 years, from weekly closing prices with dividends included.
Long-term scenarios
Thousands of simulated paths from the price history. A range of outcomes, not a forecast.
Monte Carlo projection
Thousands of simulated paths for $10,000 in MOH, from its own past volatility. The shaded area holds 80% of them.
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in MOH today could grow to about $23,621 by 2036 in the base case, with a 90th-percentile outcome near $126,990 and a 10th-percentile outcome around $4,394. Projections are statistical simulations, not guarantees.
MOH Stock Price Prediction: 2030
The same simulation in share prices, year by year.
CleaRank's simulation projects a price near $292 for MOH by 2030 in the base case, from $207 today (1.4x over 4 years). The 10th-percentile path ends near $101. These are outcomes of a Monte Carlo simulation run on MOH's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | 10th percentile | Base case | 90th percentile | range base today |
|---|---|---|---|---|
| 2027 | $133 | $226 | $385 | |
| 2028 | $116 | $246 | $522 | |
| 2029 | $107 | $268 | $674 | |
| 2030 | $101 | $292 | $847 | |
| 2031 | $97.02 | $319 | $1,047 |
Method: a lognormal simulation of MOH's own volatility and capped historical trend, re-run daily; base case is the median path, the outer columns the 10th and 90th percentiles.
Insider trading
What the people running the company have bought and sold.
MOH insider trading
Shares the company's directors and officers bought and sold, from their own filings.
Month by month
Open-market purchases above the line, sales below.
Insider buying: Insiders bought $1.7M on the open market and sold $32.7M.
As of October 17, 2026, MOH insiders reported 9 open-market sales worth $32.7M and 2 open-market purchases worth $1.7M over the last 18 months; grants and option exercises are not counted.
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Oct 1, 2026 | Barbara L. Brasier
Director
|
Grant | 304 | $55.0K |
| Jul 1, 2026 | Barbara L. Brasier
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Leo P Grohowski
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Stephen H Lockhart
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Steven J Orlando
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Ronna E Romney
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Richard M Schapiro
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Francis S Soistman Jr
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Dale B Wolf
Director
|
Grant | 237 | $55.1K |
| Jul 1, 2026 | Richard C Zoretic
Director
|
Grant | 237 | $55.1K |
| Jun 30, 2026 | Debra Bacon
Officer
|
Grant | 23 | $5.3K |
| Jun 30, 2026 | Jeff D Barlow
Officer
|
Grant | 138 | $31.6K |
| Jun 30, 2026 | James E Woys
Chief Operating Officer
|
Grant | 144 | $32.9K |
| May 14, 2026 | Maurice S Hebert
Officer
|
Sell | 600 | $114.9K |
| May 11, 2026 | Jeff D Barlow
Officer
|
Sell | 17.8K | $3.3M |
| May 6, 2026 | Francis S Soistman Jr
Director
|
Grant | 170 | $33.6K |
| Apr 1, 2026 | Barbara L. Brasier
Director
|
Grant | 405 | $55.0K |
| Apr 1, 2026 | Leo P Grohowski
Director
|
Grant | 405 | $55.0K |
| Apr 1, 2026 | Stephen H Lockhart
Director
|
Grant | 405 | $55.0K |
| Apr 1, 2026 | Steven J Orlando
Director
|
Grant | 405 | $55.0K |
| Apr 1, 2026 | Ronna E Romney
Director
|
Grant | 405 | $55.0K |
| Apr 1, 2026 | Richard M Schapiro
Director
|
Grant | 405 | $55.0K |
| Apr 1, 2026 | Dale B Wolf
Director
|
Grant | 405 | $55.0K |
| Apr 1, 2026 | Richard C Zoretic
Director
|
Grant | 405 | $55.0K |
| Mar 12, 2026 | Ronna E Romney
Director
|
Sell | 506 | $74.3K |
| Feb 27, 2026 | Debra Bacon
Officer
|
Grant | 9.6K | $1.4M |
| Feb 27, 2026 | Jeff D Barlow
Officer
|
Grant | 13.7K | $2.0M |
| Feb 27, 2026 | Maurice S Hebert
Officer
|
Grant | 2.7K | $400.1K |
| Feb 27, 2026 | Mark Lowell Keim
Chief Financial Officer
|
Grant | 26.1K | $3.8M |
| Feb 27, 2026 | James E Woys
Chief Operating Officer
|
Grant | 17.0K | $2.5M |
| Feb 27, 2026 | Joseph M. Zubretsky
Chief Executive Officer
|
Grant | 66.4K | $9.7M |
| Feb 11, 2026 | Richard C Zoretic
Director
|
Buy | 800 | $100.1K |
| Dec 31, 2025 | Debra Bacon
Officer
|
Grant | 22 | $3.2K |
| Dec 31, 2025 | Barbara L. Brasier
Director
|
Grant | 317 | $55.0K |
| Dec 31, 2025 | Leo P Grohowski
Director
|
Grant | 317 | $55.0K |
| Dec 31, 2025 | Stephen H Lockhart
Director
|
Grant | 317 | $55.0K |
| Dec 31, 2025 | Steven J Orlando
Director
|
Grant | 317 | $55.0K |
| Dec 31, 2025 | Ronna E Romney
Director
|
Grant | 317 | $55.0K |
| Dec 31, 2025 | Richard M Schapiro
Director
|
Grant | 317 | $55.0K |
| Dec 31, 2025 | Dale B Wolf
Director
|
Grant | 317 | $55.0K |
| Dec 31, 2025 | Richard C Zoretic
Director
|
Grant | 317 | $55.0K |
| Nov 24, 2025 | Richard M Schapiro
Director
|
Sell | 357 | $51.1K |
| Oct 1, 2025 | Barbara L. Brasier
Director
|
Grant | 285 | $54.9K |
| Oct 1, 2025 | Leo P Grohowski
Director
|
Grant | 285 | $54.9K |
| Oct 1, 2025 | Stephen H Lockhart
Director
|
Grant | 285 | $54.9K |
| Oct 1, 2025 | Steven J Orlando
Director
|
Grant | 285 | $54.9K |
| Oct 1, 2025 | Ronna E Romney
Director
|
Grant | 285 | $54.9K |
| Oct 1, 2025 | Richard M Schapiro
Director
|
Grant | 285 | $54.9K |
| Oct 1, 2025 | Dale B Wolf
Director
|
Grant | 285 | $54.9K |
| Oct 1, 2025 | Richard C Zoretic
Director
|
Grant | 285 | $54.9K |
| Aug 6, 2025 | Ronna E Romney
Director
|
Sell | 700 | $107.6K |
| Aug 4, 2025 | James E Woys
Chief Operating Officer
|
Buy | 10.0K | $1.6M |
| Jul 1, 2025 | Barbara L. Brasier
Director
|
Grant | 180 | $55.1K |
| Jul 1, 2025 | Leo P Grohowski
Director
|
Grant | 180 | $55.1K |
| Jul 1, 2025 | Stephen H Lockhart
Director
|
Grant | 180 | $55.1K |
| Jul 1, 2025 | Steven J Orlando
Director
|
Grant | 180 | $55.1K |
| Jul 1, 2025 | Ronna E Romney
Director
|
Grant | 180 | $55.1K |
| Jul 1, 2025 | Richard M Schapiro
Director
|
Grant | 180 | $55.1K |
| Jul 1, 2025 | Dale B Wolf
Director
|
Grant | 180 | $55.1K |
| Jul 1, 2025 | Richard C Zoretic
Director
|
Grant | 180 | $55.1K |
| Jun 30, 2025 | Debra Bacon
Officer
|
Grant | 41 | $10.1K |
| Jun 30, 2025 | Jeff D Barlow
Officer
|
Grant | 85 | $21.0K |
| Jun 30, 2025 | James E Woys
Chief Operating Officer
|
Grant | 85 | $21.0K |
| May 21, 2025 | Dale B Wolf
Director
|
Sell | 1.5K | $484.3K |
| May 5, 2025 | Steven J Orlando
Director
|
Sell | 1.0K | $318.6K |
| May 1, 2025 | Leo P Grohowski
Director
|
Grant | 118 | $36.9K |
| Apr 30, 2025 | Joseph M Zubretsky
Chief Executive Officer
|
Sell | 87.5K | $28.0M |
| Apr 29, 2025 | Richard M Schapiro
Director
|
Sell | 669 | $214.4K |
Source: TwelveData, from SEC Form 4 filings
Questions people ask
Answered from the figures on this page, as of October 17, 2026.